drugset / Trial / NCT07219121
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and efficacy of sparsentan tablets for the treatment of patients with proteinuria after kidney transplantation with once-daily dosing for 36 weeks.
Timeline
- Start
- 2025-10-07
- Primary completion
- 2027-03
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sparsentan | Small molecule | 400 mg | Oral |
| Subject | Sparsentan | Small molecule | 800 mg | Oral |